Parkinson's disease-cognitive rating scale: Psychometrics for mild cognitive impairment

Movement Disorders

Volumn 28, Issue 10, 2013, Pages 1376-1383

  Fernández de Bobadilla, Ramón ^a,b,c   Pagonabarraga, Javier ^a,b,d   Martínez Horta, Saül ^a,b   Pascual Sedano, Berta ^a,b,d   Campolongo, Antonia ^a,b   Kulisevsky, Jaime ^a,b,c,d  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Cutoff; Mild cognitive impairment; Parkinson's disease; Parkinson's Disease Cognitive Rating Scale; Responsiveness

Indexed keywords

LEVODOPA;

AGE; AGED; AREA UNDER THE CURVE; ARTICLE; ATTENTION; CLINICAL ASSESSMENT TOOL; CLINICAL DEMENTIA RATING; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; DRAWING; EDUCATION; GENDER; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MATTIS DEMENTIA RATING SCALE 2; MILD COGNITIVE IMPAIRMENT; MULTICENTER STUDY; OBSERVATIONAL STUDY; PARKINSON DISEASE; PARKINSON DISEASE COGNITIVE RATING SCALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; UNIFIED PARKINSON DISEASE RATING SCALE; VERBAL MEMORY; WORKING MEMORY;

CUTOFF; MILD COGNITIVE IMPAIRMENT; PARKINSON'S DISEASE; PARKINSON'S DISEASE-COGNITIVE RATING SCALE; RESPONSIVENESS;

AGED; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; FEMALE; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PROSPECTIVE STUDIES; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 84884715294     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25568     Document Type: Article

References (50)

1. Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 2011;82:1112-1118.
2. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Dis 2008;23:837-844.
3. Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009;72:1121-1126.
4. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004;127(pt 3):550-560.
5. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005;65:1239-1245.
6. Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Dis 2007;22:1272-1277.
7. Dalrymple-Alford JC, Livingston L, MacAskill MR, et al. Characterizing mild cognitive impairment in Parkinson's disease. Mov Dis 2011;26:629-636.
8. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Dis 2006;21:1343-1349.
9. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010;75:1062-1069.
10. Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Dis 2011;26:1814-1824.
11. Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Dis 2012;27:349-356.
12. Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010;75:1717-1725.
13. Hoops S, Nazem S, Siderowf AD, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2009;73:1738-1745.
14. Verbaan D, Jeukens-Visser M, Van Laar T, et al. SCOPA-cognition cutoff value for detection of Parkinson's disease dementia. Mov Dis 2011;26:1881-1886.
15. Llebaria G, Pagonabarraga J, Kulisevsky J, et al. Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease. Mov Dis 2008;23:1546-1550.
16. Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A. Parkinson's Disease-Cognitive Rating Scale: a new cognitive scale specific for Parkinson's disease. Mov Dis 2008;23:998-1005.
17. Martinez-Martin P, Prieto-Jurczynska C, Frades-Payo B. [Psychometric attributes of the Parkinson's Disease-Cognitive Rating Scale. An independent validation study]. Revista Neurologia 2009;49:393-398.
18. Matteau E, Dupre N, Langlois M, Provencher P, Simard M. Clinical validity of the Mattis Dementia Rating Scale-2 in Parkinson disease with MCI and dementia. J Geriatr Psychiatry Neurol 2012;25:100-106.
19. Villeneuve S, Rodrigues-Brazete J, Joncas S, Postuma RB, Latreille V, Gagnon JF. Validity of the Mattis Dementia Rating Scale to detect mild cognitive impairment in Parkinson's disease and REM sleep behavior disorder. Dement Geriatr Cogn Dis 2011;31:210-217.
20. Troster AI, Woods SP, Morgan EE. Assessing cognitive change in Parkinson's disease: development of practice effect-corrected reliable change indices. Arch Clin Neurol 2007;22:711-718.
21. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132(pt 11):2958-2969.
22. Kulisevsky J, Pagonabarraga J. Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Mov Dis 2009;24:1103-1110.
23. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-148.
24. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Dis 2007;22:2314-2324.
25. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Dis 2010;25:2649-2653.
26. Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Dis 2007;22:41-47.
27. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
28. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-370.
29. Schmidt R, Freidl W, Fazekas F, et al. The Mattis Dementia Rating Scale: normative data from 1, 001 healthy volunteers. Neurology 1994;44:964-966.
30. Pagonabarraga J, Corcuera-Solano I, Vives-Gilabert Y, et al. Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson's disease [serial online]. PLoS One 2013;8:e54980.
31. Pedraza O, Lucas JA, Smith GE, Petersen RC, Graff-Radford NR, Ivnik RJ. Robust and expanded norms for the Dementia Rating Scale. Arch Clin Neuropsychol 2010;25:347-358.
32. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-1146.
33. Guy W. The Clinician Global Severity and Impression scales. In: Guy W, ed. ECDEU Impression and for Psychopharmacology. Washington, DC: Superintendent of Documents, US Government Printing Office, US Department of Health, Education, and Welfare Publication; 1976:218-222.
34. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Orlando, FL: Academic Press Inc.; 1977.
35. Shulman LM, Gruber-Baldini AL, Anderson KE, Fishman PS, Reich SG, Weiner WJ. The clinically important difference on the Unified Parkinson's Disease Rating Scale. Arch Neurol 2010;67:64-70.
36. Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Eidemiol 2003;56:395-407.
37. Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999;15:141-155.
38. Norman GR. The relation between the minimally important difference and patient benefit. COPD 2005;2:69-73.
39. Copay AG, Subach BR, Glassman SD, Polly DW Jr, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 2007;7:541-546.
40. Troster AI. A precis of recent advances in the neuropsychology of mild cognitive impairment(s) in Parkinson's disease and a proposal of preliminary research criteria. J Int Neuropsychol Soc 2011;8:1-14.
41. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991;59:12-19.
42. Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987;40:171-178.
43. Lauridsen HH, Hartvigsen J, Manniche C, Korsholm L, Grunnet-Nilsson N. Responsiveness and minimal clinically important difference for pain and disability instruments in low back pain patients [serial online]. BMC Musculoskel Dis 2006;7:82.
44. Jordan K, Dunn KM, Lewis M, Croft P. A minimal clinically important difference was derived for the Roland-Morris disability questionnaire for low back pain. J Clin Epidemiol 2006;59:45-52.
45. Shulman LM. Levodopa toxicity in Parkinson disease: reality or myth? Reality-practice patterns should change. Arch Neurol 2000;57:406-407; discussion 410.
46. Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012;78:1434-1440.
47. Nishio Y, Hirayama K, Takeda A, et al. Corticolimbic gray matter loss in Parkinson's disease without dementia. Eur J Neurol 2010;17:1090-1097.
48. Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology 2006;67:1605-1611.
49. Johnson DK, Galvin JE. Longitudinal changes in cognition in Parkinson's disease with and without dementia. Dement Geriatr Cogn Dis 2011;31:98-108.
50. Hebben N, Millberg W, eds. Essentials of Neuropsychological Assessment. 2nd ed. New York: John Wiley & Sons; 2009.